Drug Database
UN

unspecified allergy vaccine (Staloral)

✓ Approved

Stallergenes · 治疗药物

什么是 unspecified allergy vaccine?

unspecified allergy vaccine 是一种治疗药物,由Stallergenes研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Oral (PO)、Subcutaneous Injection、Sublingual (SL)/Oral Transmucosal。

药物档案

商品名Staloral
公司Stallergenes
给药途径Injectable (Others), Oral (PO), Subcutaneous Injection, Sublingual (SL)/Oral Transmucosal
状态Approved

治疗适应症

unspecified allergy vaccine 针对 2 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Respiratory, thoracic and mediastinal disordersAsthma✓ Approved
Respiratory, thoracic and mediastinal disordersRhinitis allergic✓ Approved

相关研究文献

PubMedJournal of oral & facial pain and headache2026-08-04

The impact of climatic factors on headache patterns: a 14-year time series analysis of cluster and tension-type headaches in primary care.

Cuenca-Zaldívar Juan Nicolás JN, Corral Del Villar Carmen C, García Torres Silvia S, Araujo Zamora Rafael R et al.

Weather-related influences on pain and neurological symptoms are widely discussed in biometeorology. However, the long-term impact of climatic variables on primary care headache consultations remains unclear. This study aimed to examine whether climatic variables are associated with consultations for cluster headaches, tension-type headaches (TTH), and unspecified headaches over 14 years. Data (2010-2023) were extracted from medical records using International Classification of Primary Care, Second Edition (ICPC-2) codes. Meteorological variables (temperature, rainfall, wind direction, barometric pressure, and sunshine hours) were obtained from the State Meteorological Agency. Time-series analyses used Exponential Smoothing State Space Model with External Regressors (ETSX) and AutoRegressive Integrated Moving Average Models with External Regressors (ARIMAX) using age, sex, and meteorological factors as external regressors. Model accuracy was evaluated using the Root Mean Squared Error (RMSE), Symmetric Mean Absolute Percentage Error (SMAPE), and Mean Absolute Scaled Error (MASE). A total of 5127 headache consultations were analyzed (mean age, 45.0 ± 19.9 years; 68.9% female). ETSX models best fit the overall, unspecified, and cluster headache series, whereas the ARIMAX model provided optimal performance for TTH. Sex was the strongest predictor across all models. In TTH, female sex increased consultations (p < 0.001), whereas higher temperature (p = 0.031) and wind direction (cosine component; p = 0.027) were associated with fewer consultations. For cluster headache, male sex was associated with fewer consultations (p = 0.020), and no climatic variables showed a significant association. Meteorological variables were not independently associated with unspecified headache consultations. Climatic variables showed limited, subtype-specific associations, with only temperature and wind direction independently associated with TTH. No weather variables predicted cluster headache or unspecified consultations. Demographic factors appeared to be more strongly associated with healthcare utilization than climatic variables, although ETSX and ARIMAX models may support forecasting and resource planning.

PMID 42548104
阅读全文 →
PubMedAllergy, asthma & immunology research2026-08-04

Real-World Performance of Non-Allergist-Led Penicillin Allergy Delabeling: Prospective Head-to-Head Comparison of APAAACI vs. PENFAST.

Chung Freya Kl FK, Shi Weihong W, Chong Man Yui MY, Lee Elaine E et al.

Although around 90% of penicillin allergies are mislabelled, delabeling initiatives have been hindered by limited access to drug allergy services. Asia Pacific Association of Allergy, Asthma, and Clinical Immunology (APAAACI) and PENFAST risk-stratification tools can facilitate non-allergist delabeling, but their comparative real-world performance remains unknown. The purpose of this study was to prospectively evaluate APAAACI and PENFAST against allergist assessment and drug provocation testing (DPT) outcomes. In a blinded, head-to-head study, 103 adults with penicillin allergy labels underwent independent risk stratification using both APAAACI and PENFAST tools, followed by allergist evaluation and allergy testing (skin tests, in vitro tests, and DPT). We assessed diagnostic performance (area under the curve [AUC]-receiver operating characteristic, accuracy, sensitivity, specificity, positive and negative predictive values [NPVs]) and agreement (Cohen's κ) of these tools. Overall, allergist assessment demonstrated the highest AUC of 0.82 (95% confidence interval [CI], 0.69-0.95), outperforming APAAACI (AUC, 0.79; 95% CI, 0.66-0.92; P = 0.012) and PENFAST (AUC, 0.75; 95% CI, 0.62-0.89; P = 0.010). Both APAAACI and PENFAST demonstrated high sensitivity (0.88) and NPV (APAAACI, 0.99; PENFAST, 0.98), missing only one non-severe DPT-positive case. APAAACI showed excellent agreement with allergist assessment (κ = 0.96, P < 0.001) versus moderate agreement for PENFAST (κ = 0.43). Allergist evaluation had superior specificity (0.77 vs. 0.71 [APAAACI] and 0.63 [PENFAST]) and overall accuracy (0.78 vs. 0.72 and 0.65). APAAACI and PENFAST can both effectively identify low-risk patients labelled with penicillin allergy when used by non-allergists, with comparable sensitivity to allergist assessment. APAAACI's stronger agreement with allergist assessment may suggest particular utility in Asian populations. These tools can significantly improve access to delabeling in settings lacking specialist allergy services.

PMID 42547471
阅读全文 →
PubMedAllergy, asthma & immunology research2026-08-04

Predictive Biomarker for Persistent Food Allergy in Children.

Ahn Kangmo K

PMID 42547462
阅读全文 →
PubMedActa dermato-venereologica2026-08-04

Commentary on "Reported Penicillin Allergy Affects the Length of Hospital Stay in Patients with Erysipelas".

Lai Tingsong T, Li Changqiang C

PMID 42549606
阅读全文 →
PubMedThe Lancet. Infectious diseases2026-08-04

Efficacy, immunogenicity, and safety of the 9-valent human papillomavirus vaccine in males aged 16-26 years in Japan: a randomised, double-blind, placebo-controlled trial.

Hisamoto Koji K, Yamanaka Masaki M, Nomura Masayasu M, Kanno Nobufumi N et al.

Efficacy of the nine-valent human papillomavirus (9vHPV; HPV6, 11, 16, 18, 31, 33, 45, 52, and 58) vaccine was shown in females and inferred for males through immunobridging. We evaluated the efficacy of the 9vHPV vaccine in males aged 16-26 years. This randomised, double-blind, placebo-controlled, efficacy, immunogenicity, and safety phase 3 trial was conducted at 22 clinical research, hospital, medical, or treatment sites in Japan, with masking of investigators, sponsor personnel, and participants. Healthy males aged 16-26 years with no history of human papillomavirus (HPV)-related lesions and no previous HPV vaccination were randomly assigned (1:1) centrally, using permutated blocks (block sizes of four), to receive three intramuscular injections of the 9vHPV vaccine or placebo (saline) at day 1, month 2, and month 6. The primary and secondary efficacy endpoints were the combined incidences of 6-month anogenital persistent infection related to HPV6, 11, 16, and 18 and HPV31, 33, 45, 52, and 58. Anogenital swabs and external genital tissue samples were tested for the presence of HPV DNA. Tissue samples were adjudicated for histopathology diagnosis. The primary and secondary efficacy evaluations were tested for superiority with a margin of 0% in the per-protocol population. Another secondary endpoint was antibody responses to each vaccine-targeted HPV type at month 7; immunogenicity analyses were conducted in the per-protocol immunogenicity population. Safety was assessed in participants who received at least one dose of vaccine or placebo. This study is registered with ClinicalTrials.gov (NCT04635423) and is completed. Between Nov 30, 2020, and Dec 25, 2021, 1059 participants were enrolled and randomly assigned to receive the 9vHPV vaccine (n=529) or placebo (n=530). Vaccine efficacy for the primary and secondary endpoints was 89·3% (95% CI 55·4-98·2; p=0·0002) and 63·5% (2·7-86·0; p=0·023), respectively, in the initial efficacy analysis based on a visit cutoff date of Dec 29, 2023, and 91·6% (67·7-98·6) and 72·9% (38·7-89·3) in the end-of-study efficacy analysis based on a visit cutoff date of July 16, 2024. Seroconversion rates were greater than 98% for each vaccine-targeted HPV type. Injection-site adverse events were reported in 370 (70%) of 529 9vHPV vaccine recipients and 162 (31%) of 530 placebo recipients, and vaccine-related systemic adverse events in 58 (11%) vaccine recipients and 52 (10%) placebo recipients; most cases were mild or moderate. No deaths, vaccine-related serious adverse events, or discontinuations due to adverse events were reported. The 9vHPV vaccine prevents anogenital persistent infection related to vaccine-targeted HPV types in males and has an acceptable safety profile. These findings support the use of the 9vHPV vaccine in males to prevent HPV-related anogenital diseases. Merck Sharp & Dohme. For the Japanese translation of the abstract see Supplementary Material section.

PMID 42546724
阅读全文 →
PubMedClinics in geriatric medicine2026-08-04

Vaccine-Preventable Diseases in Older Adults.

Al-Jabri Maha M, Rosero Christian C, Saade Elie A EA

Older adults are at an increased risk of vaccine-preventable diseases partly because of physiologic changes in the immune and other body systems related to age and/or accumulating comorbidities that increase the vulnerability to infections and decrease the response to vaccines. Strategies to improve the response to vaccines include using a higher antigenic dose (such as in the high-dose inactivated influenza vaccines) as well as adding adjuvants (such as MF59 in the adjuvanted inactivated influenza vaccine).

PMID 42547175
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多unspecified allergy vaccine